GlassScriptPhysician profile
Lucia E Pacheco
NPI 1548640253
$2,840.63
in general payments reported to CMS, 2019-2025
30 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $463 · 2021: $387 · 2022: $603 · 2023: $551 · 2024: $232 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $823.91 | 2019-2023 | |
| Astellas Pharma US INC | $226.91 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $201.09 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $165.65 | 2020-2023 | |
| Myovant Sciences INC. | $163.57 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $157.17 | 2023-2025 | Myfembree |
| Boston Scientific Corporation | $106.57 | 2020 | |
| Organon LLC | $103.92 | 2021-2022 | |
| Hologic Sales and Service, LLC | $96.24 | 2020-2025 | Novasure, Fluent Fluid Management System, Acessa Provu System |
| Coopersurgical, INC. | $83.78 | 2019-2025 | Paragard T 380a |
| Caldera Medical, INC | $81.13 | 2023 | Desara |
| Agile Therapeutics, INC. | $66.54 | 2021 | |
| Sage Therapeutics, LLC | $66.53 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $61.13 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $57.65 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $50.53 | 2020-2022 | |
| Aspira Women'S Health INC | $36.13 | 2022-2024 | Ova1 |
| Evofem Biosciences, INC. | $35.60 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.13 | 2021-2023 | Gardasil 9 |
| Smith+Nephew, INC. | $28.60 | 2024 | Pico 7 |
| Mylan Pharmaceuticals INC. | $28.17 | 2019-2021 | |
| Lupin INC. | $24.22 | 2020 | |
| Axonics, INC. | $23.65 | 2024 | Axonics |
| Allergan, INC. | $23.14 | 2019 | |
| Medtronic, INC. | $22.27 | 2023 | V-Loc 180 |
| Pfizer INC. | $17.56 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.50 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.84 | 2025 | Unithroid |
| Amgen INC. | $14.29 | 2023 | Prolia |
| Renovia INC | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucia Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.